company background image
EAH

ECO Animal Health GroupAIM:EAH Stock Report

Market Cap

UK£106.7m

7D

-17.7%

1Y

-31.3%

Updated

01 Dec, 2021

Data

Company Financials +
EAH fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends0/6

EAH Stock Overview

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide.

Price History & Performance

Summary of all time highs, changes and price drops for ECO Animal Health Group
Historical stock prices
Current Share PriceUK£1.65
52 Week HighUK£4.05
52 Week LowUK£1.40
Beta0.62
1 Month Change-37.74%
3 Month Change-52.86%
1 Year Change-31.25%
3 Year Change-62.71%
5 Year Change-67.65%
Change since IPO395.00%

Recent News & Updates

Nov 16
ECO Animal Health Group plc (LON:EAH) Shares Could Be 48% Below Their Intrinsic Value Estimate

ECO Animal Health Group plc (LON:EAH) Shares Could Be 48% Below Their Intrinsic Value Estimate

How far off is ECO Animal Health Group plc ( LON:EAH ) from its intrinsic value? Using the most recent financial data...

Shareholder Returns

EAHGB PharmaceuticalsGB Market
7D-17.7%-1.6%-2.6%
1Y-31.3%8.4%10.9%

Return vs Industry: EAH underperformed the UK Pharmaceuticals industry which returned 9.2% over the past year.

Return vs Market: EAH underperformed the UK Market which returned 13.8% over the past year.

Price Volatility

Is EAH's price volatile compared to industry and market?
EAH volatility
EAH Average Weekly Movement7.7%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.8%
10% least volatile stocks in GB Market2.5%

Stable Share Price: EAH is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: EAH's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
1972207Marc Loomeshttps://www.ecoanimalhealthgroupplc.com

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle.

ECO Animal Health Group Fundamentals Summary


Earnings & Revenue

Key profitability statistics from the latest earnings report
EAH income statement (TTM)
RevenueUK£101.55m
Cost of RevenueUK£50.85m
Gross ProfitUK£50.70m
ExpensesUK£45.14m
EarningsUK£5.57m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.082
Gross Margin49.93%
Net Profit Margin5.48%
Debt/Equity Ratio0%

How did EAH perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

12%

Payout Ratio

Valuation

Is ECO Animal Health Group undervalued compared to its fair value and its price relative to the market?

20.08x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: EAH (£1.58) is trading below our estimate of fair value (£1.63)

Significantly Below Fair Value: EAH is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: EAH is good value based on its PE Ratio (19.2x) compared to the UK Pharmaceuticals industry average (29.7x).

PE vs Market: EAH is poor value based on its PE Ratio (19.2x) compared to the UK market (19x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EAH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EAH is good value based on its PB Ratio (1.3x) compared to the GB Pharmaceuticals industry average (4.5x).


Future Growth

How is ECO Animal Health Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

5.3%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if EAH's forecast earnings growth is above the savings rate (0.9%).

Earnings vs Market: Insufficient data to determine if EAH's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: EAH's revenue (5.3% per year) is forecast to grow faster than the UK market (4.9% per year).

High Growth Revenue: EAH's revenue (5.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EAH's Return on Equity is forecast to be high in 3 years time


Past Performance

How has ECO Animal Health Group performed over the past 5 years?

-13.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EAH has high quality earnings.

Growing Profit Margin: EAH's current net profit margins (5.5%) are lower than last year (6%).


Past Earnings Growth Analysis

Earnings Trend: EAH's earnings have declined by 13.7% per year over the past 5 years.

Accelerating Growth: EAH's earnings growth over the past year (6.7%) exceeds its 5-year average (-13.7% per year).

Earnings vs Industry: EAH earnings growth over the past year (6.7%) exceeded the Pharmaceuticals industry -20.6%.


Return on Equity

High ROE: EAH's Return on Equity (12.9%) is considered low.


Financial Health

How is ECO Animal Health Group's financial position?


Financial Position Analysis

Short Term Liabilities: EAH's short term assets (£80.7M) exceed its short term liabilities (£21.1M).

Long Term Liabilities: EAH's short term assets (£80.7M) exceed its long term liabilities (£420.0K).


Debt to Equity History and Analysis

Debt Level: EAH is debt free.

Reducing Debt: EAH had no debt 5 years ago.

Debt Coverage: EAH has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: EAH has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is ECO Animal Health Group current dividend yield, its reliability and sustainability?

0.61%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: EAH's dividend (0.63%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.37%).

High Dividend: EAH's dividend (0.63%) is low compared to the top 25% of dividend payers in the UK market (4.17%).


Stability and Growth of Payments

Stable Dividend: EAH is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.

Growing Dividend: EAH is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: EAH is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EAH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average board tenure


CEO

Marc Loomes (60 yo)

11.83yrs

Tenure

UK£541,000

Compensation

Mr. Marc Denham Loomes, BVSc, MRCVS, serves as Chief Executive Officer of ECO Animal Health Group Plc since 2010. Mr. Loomes has been a Global Director of Anti-Parasitic Products and Managing Director of E...


CEO Compensation Analysis

Compensation vs Market: Marc's total compensation ($USD716.32K) is above average for companies of similar size in the UK market ($USD324.53K).

Compensation vs Earnings: Marc's compensation has increased by more than 20% in the past year.


Board Members

Experienced Board: EAH's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ECO Animal Health Group plc's employee growth, exchange listings and data sources


Key Information

  • Name: ECO Animal Health Group plc
  • Ticker: EAH
  • Exchange: AIM
  • Founded: 1972
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£106.662m
  • Shares outstanding: 67.72m
  • Website: https://www.ecoanimalhealthgroupplc.com

Number of Employees


Location

  • ECO Animal Health Group plc
  • 78 Coombe Road
  • New Malden
  • Greater London
  • KT3 4QS
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/01 18:53
End of Day Share Price2021/12/01 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.